| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/16/2004 | CN1153780C Protein with thrombopoiesis substance activity |
| 06/16/2004 | CN1153770C Substitued nitrogen heterocyclic ring as inhibitors of P38 protein kinase |
| 06/16/2004 | CN1153768C Process for extracting medicinal component from pueraria root |
| 06/16/2004 | CN1153759C Novel delta-amino-gamma-hydroxy-omega-aryl-alkane amide compounds |
| 06/16/2004 | CN1153581C Ointment for curing piles |
| 06/16/2004 | CN1153569C Use of fumaric acid derivatives |
| 06/15/2004 | US6750360 Lipoxin compounds and their use in treating cell proliferative disorders |
| 06/15/2004 | US6750253 Aminobenzophenones as inhibitors of il-1β and tnf-α |
| 06/15/2004 | US6750252 Tri-substituted phenyl derivatives and analogues |
| 06/15/2004 | US6750248 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 06/15/2004 | US6750239 Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750232 2-aminopyridine compounds and use thereof as drugs |
| 06/15/2004 | US6750228 Uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions |
| 06/15/2004 | US6750221 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 06/15/2004 | US6750219 Having integrin alpha v beta 3 antagonistic activity, gp iib/iiia antagonistic activity, and/or human platelet aggregation inhibitory activity and also having excellent water solubility |
| 06/15/2004 | US6750217 Anticancer agents; cardiovascular disorders; kinase inhibitor |
| 06/15/2004 | US6750214 Quinoline and quinazoline compounds useful in therapy |
| 06/15/2004 | US6750202 Inhibitors of procollagen c-proteinase (pcp), for treating fibrosis of the liver |
| 06/15/2004 | US6750044 For producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from native vegf protein |
| 06/15/2004 | US6749851 Applying radiation |
| 06/15/2004 | US6749587 Modular infusion device and method |
| 06/15/2004 | CA2313302C New metalloprotease inhibitors, the process for preparing them and the pharmaceutical compounds containing them |
| 06/15/2004 | CA2192714C Quasiturbine (qurbine) zero vibration - continuous combustion rotary engine, compressor and pump |
| 06/15/2004 | CA2153195C New benzopyran derivatives; process for preparing the same and pharmaceutical compositions containing them |
| 06/15/2004 | CA2094858C Method of treating hyperproliferative vascular disease |
| 06/15/2004 | CA2086642C Method of treating hyperproliferative vascular disease |
| 06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
| 06/10/2004 | WO2004049095A2 Betaine and salicylic acid compositions |
| 06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
| 06/10/2004 | WO2004048512A2 Novel proteins and nucleic acids encoding same |
| 06/10/2004 | WO2004048401A1 Peptides and medicinal compositions containing the same |
| 06/10/2004 | WO2004048400A1 Peptide gap junction modulators |
| 06/10/2004 | WO2004048391A1 Silicon compounds to be used as ligands for retinoid receptors |
| 06/10/2004 | WO2004048386A2 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS |
| 06/10/2004 | WO2004048383A1 Mixed lineage kinase modulators |
| 06/10/2004 | WO2004048375A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 06/10/2004 | WO2004048368A2 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
| 06/10/2004 | WO2004048366A1 2-oxoindoline derivatives |
| 06/10/2004 | WO2004048363A1 Imidazole derivative, process for producing the same, and use |
| 06/10/2004 | WO2004048339A1 Isoquinoline compounds and medicinal use thereof |
| 06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
| 06/10/2004 | WO2004047858A1 Novel use of erythropoietin in heart diseases |
| 06/10/2004 | WO2004047851A1 Method of inhibiting cell death, cell death inhibitor and remedy for disease caused by cell death containing the cell death inhibitor |
| 06/10/2004 | WO2004047837A2 Beta-blockers having antioxidant and nitric oxide-donor activity |
| 06/10/2004 | WO2004047835A1 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation |
| 06/10/2004 | WO2004047824A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | WO2004047564A1 Novel pharmaceutical compositions in particular for preventing cardiovascular pathologies |
| 06/10/2004 | WO2004037776A3 Novel compounds and their use as prar-modulators |
| 06/10/2004 | WO2004032836A3 Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors |
| 06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 06/10/2004 | WO2004013285A3 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
| 06/10/2004 | WO2004010954A3 Cardioprotective therapies based on enzymatic elimination of lipid peroxides by allene oxide synthase |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004003235A3 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004002405A3 Amino-bicyclic pyrazinones and pyridinones |
| 06/10/2004 | WO2003084943A9 Terphenyl derivatives, preparation thereof, compositions containing same |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003072027A3 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 06/10/2004 | WO2003066842A3 Method for producing recombinant proteins in micro-organisms |
| 06/10/2004 | WO2003066005A3 Ansamycins having improved pharmacological and biological properties |
| 06/10/2004 | WO2003064626A3 Double-stranded oligonucleotides |
| 06/10/2004 | WO2003048116A3 Esters and amides as ppar-alpha agonists ____________ |
| 06/10/2004 | WO2002040629A3 Promoters exhibiting endothelial cell specificity and methods of using same |
| 06/10/2004 | US20040111763 for introducing DNA into organisms which produce large amounts of oils; genetic engineering; for animal feed, foods, cosmetics and pharmaceuticals; kits |
| 06/10/2004 | US20040110956 Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them |
| 06/10/2004 | US20040110952 e.g., N-[1-(3-phenyl-3-[cyclopenytlacetylamino]propyl)-4-piperidinyl]-N-ethyl-4-methanesulfonylphenylacetamide |
| 06/10/2004 | US20040110947 such as methyl-3-[([2-[(3-chloro-2,2-dimethylpropanoyl)amino]phenyl]thio)methyl]benzoate; lipid/lipoprotein metabolism |
| 06/10/2004 | US20040110946 such as ethyl-2-[6-amino-4-(1,3-benzodioxol-5-yl)-3,5-dicyano-2-pyridinyl]propionate; drug screening; for treatment of cardiovascular disorders/diabetes |
| 06/10/2004 | US20040110928 Peptide conjugates for drug delivery |
| 06/10/2004 | US20040110920 Novel g protein-coupled receptor protein and dna thereof |
| 06/10/2004 | US20040110849 for inhibiting the progression of atherosclerosis, comprising the administration of an effective anti-LDL (low density lipoproteins)-oxidation amount of phytoene, phytofluene or mixtures thereof |
| 06/10/2004 | US20040110840 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/10/2004 | US20040110832 management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc |
| 06/10/2004 | US20040110826 Alpha 2c-adrenoceptor antagonists comprising 1- (benzylamino)-1,2,4]triazolo[1,5-c]pyrimidine derivatives; Parkinson's disease, dyskinesias, antidepressants; hypotensive, antidiabetic agents; eating,sexual disorders |
| 06/10/2004 | US20040110810 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. |
| 06/10/2004 | US20040110809 di- and tricycle-substituted imidazolidine-, oxazolidine- and thiazolidine diones and thiones, e.g., 5-[p-(quinolin-3-yl)-alpha-hydroxybenzyl]-5-methylimidazolidinedione |
| 06/10/2004 | US20040110805 Sulfur compounds such as 4-[(4-{3-[(2-adamantylamino)sulfonyl]propoxy}phenyl)sulfonyl]- N-hydroxytetrahydro-2H-pyran-4-carboximide, used as antagonists for metalloenzyme and/or aggrecanase activity; tissue repair |
| 06/10/2004 | US20040110803 especially salts, prodrugs or active derivatives thereof; optionally coadministering a compound that interferes with fatty acid synthesis. |
| 06/10/2004 | US20040110794 Novel piperidine derivatives as modulators of chemokine receptors |
| 06/10/2004 | US20040110793 Heterocyclo inhibitors of potassium channel function |
| 06/10/2004 | US20040110788 A 2-azabicyclo-[2.2.1]hept-7yl derivatives, treating schizophrenia, depression, anxiety, dementia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Huntington's disease, Tourette's syndrome; chemical intermediates |
| 06/10/2004 | US20040110779 Hydantoin derivsatives with affinity for somatostatin receptors |
| 06/10/2004 | US20040110768 (S)-3-(1H-indol-3-yl)-N-(1-methoxymethyl-cyclohexylmethyl)-2-methyl-2-[4-(4-nitro-phenyl)-oxazol-2-ylamino]-propionamide for example; cancer, psychological disorders, sexual disorders, eating disorders, inflammatory bowel disease, sleep disorders |
| 06/10/2004 | US20040110763 Pyrazolopyridine compound and pharmaceutical use thereof |
| 06/10/2004 | US20040110759 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 06/10/2004 | US20040110752 2-amino-5-((hetero)aryl)-thiazole derivatives; treatment of disorders such as cancer, immunologic disorders and allergic disorders, optionally in combination with other drugs such as immunosuppressants |
| 06/10/2004 | US20040110744 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
| 06/10/2004 | US20040110736 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/10/2004 | US20040110733 Methods and agents for treating cardiovascular diseases |
| 06/10/2004 | US20040110728 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 06/10/2004 | US20040110718 Anti-HCV nucleoside derivatives |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110709 Genetic modification of the lung as a portal for gene delivery |
| 06/10/2004 | US20040110706 Nucleic acid with point mutations, deletions, insertions and/or rearrangements ; hyperthermia, myasthenia, ataxia, neuropathic and inflammatory pain; Alzheimer*s, Parkinson's disease; schizophrenia, hyperekplexia, myotonias and arrhythmia |
| 06/10/2004 | US20040110704 Decreased or deleted activity of enzyme with modified sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in reducing end; antitumor agents, cardiovascular disorders, autoimmune diseases |
| 06/10/2004 | US20040110692 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 06/10/2004 | US20040110690 Transporter peptide capable of translocating across biological membrane of pancreatic B-cells, hepatocytes, colon cells, muscle cells and/or lung cells; drug delivery; biochemical conjugation |
| 06/10/2004 | US20040110683 Cell proliferation factor Fwa267 |